Society for Hematopathology/European Association for Haematopathology 2013 Workshop-Case Requirements
The deadline for case submissions is February 14, 2013.
Notice of workshop acceptance will be sent by May 15, 2013.
The workshop panel will select approximately 100 cases, and 50 will be presented at the meeting. Early submissions are strongly encouraged.
For each case, we will request:
- One completed case submission form (available on the Case Submission & Workshop Case server website)
- One CD containing critical images of the case in PowerPoint format
- 10 H & E stained slides and 10 unstained slides (biopsy or aspirate smears)
- Representative Wright-Giemsa stained slides or digital images of peripheral blood or bone marrow aspirate smears or fine needle aspirate material can be submitted where there is limited material, such as in bone marrow or blood cases.
- Critical immunostains flow cytometry immunophenotypic, cytogenetic and molecular data
Send slides to:
Carlos Bueso-Ramos, MD PhD
Department of Hematopathology, Unit 72
The University of Texas
MD Anderson Cancer Center
1515 Holcombe Boulevard
Houton, TX 77030
Types of Cases Sought for Workshop:
- Exemplary demonstration of all WHO categories of AML, MDS and ALL using multiparameter correlations.
- Therapy-related myeloid neoplasms
- Acute leukemias of ambiguous lineage and aggressive hematolymphoid tumors with unusual clinical, morphologic, immunophenotypic, or genetic features
- Progression and transformation with phenotypic changes and genetic lesions
- Interesting, illustrative or difficult cases of reactive myeloid and lymphoid proliferations mimicking aggressive neoplasms
- Tumors treated with new therapeutic agents
Some questions to be addressed at the workshop:
- In the era of targeted therapy, what is the value of a classification system based on morphologic, immunophenotypic, and cytogenetic/molecular data?
- What should be the optimum immunophenotypic/molecular workup for cases of AML, MDS and ALL at diagnosis, remission and relapse?
- How can we apply new target discovery to the classification of AML, MDS, and ALL?
- Are there potential new diagnostic entities that need to be considered?
- Can the diagnosis of AML with myelodysplasia-related changes be refined to reduce its current biologic heterogeneity?
- What is the optimum approach for defining lineage in cases of acute leukemia of ambiguous lineage?
- What are useful predictors of disease progression and poor prognosis in AML, MDS, and ALL?